My ePortfolio Register   

ASCO 2013 /
Nivolumab blocking PD1 in lung cancer and melanoma

30th May - 3rd Jun 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.13
Views: 4037
Rating:

Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA

Dr Suzanne Topalian talks to ecancer at the ASCO 2013 Annual Meeting about anti-PD1 results of a phase I study which looked at nivolumab to inhibit the immune checkpoint, PD1. The study reported substantial responses in lung cancer and melanoma.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence